“We have been working towards a multi-indication PBS listing for nivolumab and ipilimumab with the PBAC since 2017. We have maintained momentum throughout this period as we have always understood the importance and impact of expedited access for Australian patients,” said Owen Smith, General Manager of Bristol Myers Squibb Australia and New Zealand.
PBS listing expands access to immunotherapy for Australians with advanced cancer
March 1, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News

